Dudediligence.

4D Molecular Therapeutics, Inc

FDMTNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$3,000Sep ’24$1,000Dec ’24$14,000Mar ’25$15,000Jun ’25$90,000Sep ’25$85.1MDec ’25$3.0MMar ’26$3.8MJun ’26
Net income, by quarter
−$43.8MSep ’24−$49.7MDec ’24−$48.0MMar ’25−$54.7MJun ’25−$56.9MSep ’25$19.4MDec ’25−$68.8MMar ’26−$72.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$18.0M$3.1M$20.7M$37,000$85.2M
Operating income−$71.3M−$110.0M−$112.9M−$187.8M−$159.5M
Net income−$71.3M−$107.5M−$100.8M−$160.9M−$140.1M
Operating cash flow−$69.1M−$86.7M−$75.8M−$134.6M−$109.1M
Free cash flow−$78.2M−$98.2M−$78.6M−$138.4M−$109.6M
Cash$153.0M$52.4M$249.1M$149.3M$60.2M
Debtnone on filenone on filenone on filenone on file$0.00
Shares outstanding32.2M32.6M43.1M45.8M57.6M